Merck (MRK) Hisse Özeti
Merck & Co., Inc. dünya çapında bir sağlık şirketi olarak faaliyet göstermektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 4/6 |
| Geçmiş Performans | 1/6 |
| Finansal Sağlık | 4/6 |
| Temettüler | 4/6 |
Ödüller
Risk Analizi
MRK Community Fair Values
Create NarrativeSee what 653 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$112.55
FV
0.4% aşırı değerlenmiş içsel indirim5.25%
Revenue growth p.a.
247
users have viewed this narrative2users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
Merck & Co., Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$113.00 |
| 52 Haftanın En Yüksek Seviyesi | US$125.14 |
| 52 Haftanın En Düşük Seviyesi | US$75.40 |
| Beta | 0.20 |
| 1 Aylık Değişim | -3.50% |
| 3 Aylık Değişim | -7.27% |
| 1 Yıllık Değişim | 46.79% |
| 3 Yıllık Değişim | -0.53% |
| 5 Yıllık Değişim | 46.32% |
| Halka arzdan bu yana değişim | 9,944.44% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • May 19
Merck Completes Acquisition of Terns Pharmaceuticals
Strengthening Hematology Pipeline with Breakthrough CML Therapy Candidate TERN-701 Analyst: Qudus Adsebara (Founder, Wane Investment House) Transaction Overview Merck & Co Inc (NYSE: MRK), known as MSD outside the United States and Canada, has successfully completed the acquisition of Terns Pharmaceuticals Inc following the conclusion of its cash tender offer and merger process. The acquisition reinforces Merck’s strategy of expanding its oncology and hematology pipeline through science-driven and value-enhancing business development initiatives.
Anlatı Güncellemesi • May 17
MRK: Oncology Pipeline And Terns Deal Will Shape Forward Risk Balance
Merck's analyst fair value estimate is now $129.74. Analysts link this adjustment and modestly higher assumed revenue growth and P/E multiples to recent price target increases from firms such as Wells Fargo, UBS, JPMorgan, Citi, Morgan Stanley, RBC, and Barclays following pipeline updates and the Terns acquisition.Seeking Alpha • May 16
A Futuristic Synthesis Indeed
Summary A recent paper by Merck details the industrial synthesis of enlicitide, which is a beast of a macrocyclic peptide. Just looking at the structure tells you that this must be a ferociously active molecule with huge commercial potential, because there is just no way that anyone is going to make this on scale - or find a way to make this on scale! - otherwise. Several companies have tried over the years to come up with a small-molecule approach that could lead to an orally dosed therapy as opposed to an injectable, and Merck has apparently made it over the finish line with this one. Read the full article on Seeking AlphaRecent updates
Anlatı Güncellemesi • May 19
Merck Completes Acquisition of Terns Pharmaceuticals
Strengthening Hematology Pipeline with Breakthrough CML Therapy Candidate TERN-701 Analyst: Qudus Adsebara (Founder, Wane Investment House) Transaction Overview Merck & Co Inc (NYSE: MRK), known as MSD outside the United States and Canada, has successfully completed the acquisition of Terns Pharmaceuticals Inc following the conclusion of its cash tender offer and merger process. The acquisition reinforces Merck’s strategy of expanding its oncology and hematology pipeline through science-driven and value-enhancing business development initiatives.Anlatı Güncellemesi • May 17
MRK: Oncology Pipeline And Terns Deal Will Shape Forward Risk Balance
Merck's analyst fair value estimate is now $129.74. Analysts link this adjustment and modestly higher assumed revenue growth and P/E multiples to recent price target increases from firms such as Wells Fargo, UBS, JPMorgan, Citi, Morgan Stanley, RBC, and Barclays following pipeline updates and the Terns acquisition.Seeking Alpha • May 16
A Futuristic Synthesis Indeed
Summary A recent paper by Merck details the industrial synthesis of enlicitide, which is a beast of a macrocyclic peptide. Just looking at the structure tells you that this must be a ferociously active molecule with huge commercial potential, because there is just no way that anyone is going to make this on scale - or find a way to make this on scale! - otherwise. Several companies have tried over the years to come up with a small-molecule approach that could lead to an orally dosed therapy as opposed to an injectable, and Merck has apparently made it over the finish line with this one. Read the full article on Seeking AlphaAnaliz Makalesi • May 11
Merck's (NYSE:MRK) Soft Earnings Don't Show The Whole Picture
Shareholders appeared unconcerned with Merck & Co., Inc.'s ( NYSE:MRK ) lackluster earnings report last week. Our...
Anlatı Güncellemesi • May 02
MRK: Oncology Reorg And Deals For Targeted Therapies Will Support Higher P E Multiple
Analysts nudged the Merck price target higher by a few dollars per share, reflecting updated expectations for slightly lower revenue growth, a modestly higher profit margin, and a somewhat lower future P/E multiple, supported by recent research commentary on the pipeline and business development moves. Analyst Commentary Recent research has tilted positive around Merck, with several large firms adjusting their models and price targets to reflect updated views on the pipeline, partnered programs, and business development activity.Anlatı Güncellemesi • Apr 19
Merck & Co., Inc. – Tender Offer for Terns Pharmaceuticals, Inc. (Full Acquisition Transaction)
Author: Qudus Adebara (Founder of Wane Investment House) Transaction Overview Merck & Co., Inc. (known as MSD outside the U.S. and Canada) has formally commenced a cash tender offer to acquire all outstanding shares of Terns Pharmaceuticals, Inc., following the signing of a definitive agreement on March 25, 2026.Anlatı Güncellemesi • Apr 18
MRK: Oncology Reorg And Pipeline Deals Will Support Higher Future P E Multiple
Analysts have lifted their Merck price targets by up to the mid double digits in recent weeks, citing higher modeled revenue growth, slightly stronger profit margins, and updated views on future P/E multiples as Merck advances its pipeline and business development moves. Analyst Commentary Recent Street research on Merck has been broadly constructive, with a cluster of price target revisions and fresh initiations pointing to confidence in the company’s execution, pipeline progress, and M&A activity.
Anlatı Güncellemesi • Apr 04
MRK: M&A Execution Risks Around Terns And Revolution Will Restrain Future Upside
Analysts have nudged Merck's fair value estimate higher to approximately $101.30, reflecting updated assumptions for slightly stronger revenue growth, a modestly higher profit margin, and a marginally lower future P/E. This view is supported by a wave of recent price target increases into the $130 to $150 range and fresh Outperform or Overweight initiations on the stock.Anlatı Güncellemesi • Mar 21
MRK: Pipeline Readouts And Oncology Reorg Will Support Higher Future P E Multiple
The analyst price target for Merck has been reset from $136 to $150. This reflects analysts' updated assumptions for modestly higher revenue growth, a stronger profit margin profile, and a slightly lower future P/E multiple, supported by recent research that highlights potential upside from Sac TMT, upcoming launches, and key Phase 3 readouts.Anlatı Güncellemesi • Mar 06
MRK: Keytruda Cliff And M&A Uncertainty Will Likely Curb Long Term Upside
Analysts have lifted their Merck fair value estimate from $83.00 to about $101.04, pointing to broad price target hikes across the Street and citing confidence in upcoming product launches, Phase 3 readouts, and management's approach to the Keytruda loss of exclusivity. Analyst Commentary Recent research coverage on Merck has tilted positive, with several firms lifting price targets and starting the stock with favorable ratings.Anlatı Güncellemesi • Feb 20
MRK: Pipeline Readouts And Gardasil Policy Shifts Will Shape Forward Risk Balance
Analysts have lifted their Merck fair value estimate from $115.11 to $124.88, citing a higher expected future P/E, modestly higher projected revenue growth, and a series of recent price target hikes that highlight confidence in upcoming launches and data readouts. Analyst Commentary Recent Street research around Merck points to a generally constructive tone, with many firms adjusting ratings and price targets in a way that supports a higher fair value, while still flagging a few execution and policy watchpoints for investors to track.Anlatı Güncellemesi • Feb 06
MRK: Rising Confidence In Pipeline Execution To Support Richer Future P E Multiple
Analysts have nudged our Merck fair value estimate higher to $136, reflecting a higher average price target across firms such as Scotiabank, Goldman Sachs, BMO, BofA, Citi, Wells Fargo, Bernstein, Cantor Fitzgerald, TD Cowen, and others, who cite stronger top line expectations, updated margin assumptions, and a richer future P/E multiple. Analyst Commentary Across recent research, bullish analysts are largely aligned in their view that Merck is executing well enough to support higher valuation assumptions.
Yeni Anlatı • Jan 30
The Oncology Anchor: Why Merck’s 46% Discount Defies the Keytruda Cliff
Merck’s 2026 narrative is a high-stakes drama centered on Keytruda , the world’s top-selling cancer drug. For years, the market has treated Merck like a "one-trick pony" due to the looming 2028 "patent cliff," where Keytruda will lose its legal protection and face generic competition.Anlatı Güncellemesi • Jan 23
MRK: M&A Pipeline And Gardasil Policy Shifts Will Shape Future Risk Balance
Analysts lifted their Merck fair value estimate by about $8.50 to $115.11 per share as they factor in a higher future P/E multiple, recent price target increases from several firms, and growing confidence in the company being added to BofA's "US 1 List." Analyst Commentary Recent research on Merck gives you a mix of confidence in the company’s execution and some clear areas to watch. Here is how the current commentary breaks down.Anlatı Güncellemesi • Jan 09
MRK: Cidara Flu Deal Will Likely Highlight Overstated Long Term Hopes
Narrative Update The analyst price target for Merck has moved higher to a range of about $105 to $135. Analysts point to sector re-ratings, recent upgrades to Outperform, and confidence in the company’s product pipeline and deal activity as key drivers of their updated views.Anlatı Güncellemesi • Dec 24
MRK: Cidara Flu Deal Will Likely Expose Overstated Long Term Expectations
Analysts have nudged their fair value estimate for Merck higher, lifting the price target by $1 to $83 as they factor in stronger revenue growth, improved profit margins, and a lower future P/E multiple supported by recent positive research initiations and deal activity. Analyst Commentary Street research around Merck has turned more constructive in recent weeks, with several firms highlighting an improving growth outlook and a more attractive risk reward profile.Anlatı Güncellemesi • Dec 14
Merck predicts unstoppable growth with KEYTRUDA and WINREVAIR hitting record hihs
based on Q3 resultAnlatı Güncellemesi • Dec 10
MRK: Cidara Acquisition And Patent Overhang Will Shape Future Risk Reward Balance
Analysts have modestly raised their fair value estimate for Merck to approximately $106.62 from about $104.27 per share, citing the higher Street price target of $105, growing confidence in its infectious disease and oncology pipeline, and the view that shares remain attractively valued relative to the company's long term growth prospects. Analyst Commentary Street research on Merck continues to highlight a constructive long term outlook balanced by execution and concentration risks, with recent notes refining expectations around valuation, pipeline durability, and capital allocation.Analiz Makalesi • Dec 02
Merck (NYSE:MRK) Is Increasing Its Dividend To $0.85
Merck & Co., Inc. ( NYSE:MRK ) will increase its dividend from last year's comparable payment on the 8th of January to...Anlatı Güncellemesi • Nov 26
MRK: Recent Pipeline Deals And Patent Expiry Will Shape Outlook Ahead
Analysts have raised the price target for Merck to $105 from $98, citing stronger growth prospects and a more favorable valuation because of the company’s expanding pipeline and recent strategic deals. Analyst Commentary Recent analyst commentary on Merck highlights both positive momentum and notable risks that could influence the company’s trajectory in the months ahead.Analiz Makalesi • Nov 02
Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Merck & Co., Inc. ( NYSE:MRK ) came out with its quarterly results last week, and we wanted to see how the business is...Hissedar Getirileri
| MRK | US Pharmaceuticals | US Pazar | |
|---|---|---|---|
| 7D | -0.4% | -0.1% | -0.3% |
| 1Y | 46.8% | 38.7% | 26.7% |
Getiri vs. Endüstri: MRK geçen yıl % 38.7 oranında getiri sağlayan US Pharmaceuticals sektörünü aştı.
Getiri vs Piyasa: MRK geçen yıl % 26.7 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| MRK volatility | |
|---|---|
| MRK Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: MRK son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: MRK 'nin haftalık oynaklığı ( 3% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1891 | 74,000 | Rob Davis | www.merck.com |
Merck & Co., Inc. dünya çapında bir sağlık şirketi olarak faaliyet göstermektedir. Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq adı altında çeşitli alanlarda insan sağlığı ilaçları sunmaktadır, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia ve Janumet markaları. Şirket ayrıca Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine markaları altında hayvancılık ürünleri gibi veteriner ilaçları, aşılar ve sağlık yönetimi çözümleri ve hizmetleri de sunmaktadır, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox ve Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt markaları; Allflex Livestock Intelligence çözümleri; ve Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune markaları altında eşlik eden hayvan ürünleri, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare ve Home Again markaları.
Merck & Co., Inc. Temel Bilgiler Özeti
| MRK temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$282.15b |
| Kazançlar(TTM) | US$8.94b |
| Gelir(TTM) | US$65.77b |
31.2x
F/K Oranı4.2x
P/S OranıMRK aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| MRK gelir tablosu (TTM) | |
|---|---|
| Gelir | US$65.77b |
| Gelir Maliyeti | US$15.31b |
| Brüt Kâr | US$50.46b |
| Diğer Giderler | US$41.53b |
| Kazançlar | US$8.94b |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
Aug 04, 2026
| Hisse başına kazanç (EPS) | 3.62 |
| Brüt Marj | 76.73% |
| Net Kâr Marjı | 13.59% |
| Borç/Özkaynak Oranı | 106.9% |
MRK uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
3.0%
Mevcut Temettü Verimi91%
Ödeme OranıŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/20 17:26 |
| Gün Sonu Hisse Fiyatı | 2026/05/20 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Merck & Co., Inc. 48 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| David Toung | Argus Research Company |
| Charles Butler | Barclays |
| Emily Field | Barclays |